Fennec Pharmaceuticals Appoints New CMO and CSO
Ticker: FENC · Form: 8-K · Filed: Jul 2, 2024 · CIK: 1211583
| Field | Detail |
|---|---|
| Company | Fennec Pharmaceuticals Inc. (FENC) |
| Form Type | 8-K |
| Filed Date | Jul 2, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $8.03 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, personnel
TL;DR
Fennec Pharma shuffles top medical and science execs, Yost out, Wildfire and Davies in.
AI Summary
Fennec Pharmaceuticals Inc. announced on June 30, 2024, the appointment of Dr. Adrian J. Wildfire as Chief Medical Officer and Dr. Robert J. B. Davies as Chief Scientific Officer. The company also reported the departure of Dr. Michael J. Yost as Chief Medical Officer. These changes are effective immediately.
Why It Matters
Key leadership changes in medical and scientific roles can signal shifts in the company's research and development strategy or focus.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially in scientific and medical roles, can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Fennec Pharmaceuticals Inc. (company) — Registrant
- Dr. Adrian J. Wildfire (person) — Appointed Chief Medical Officer
- Dr. Robert J. B. Davies (person) — Appointed Chief Scientific Officer
- Dr. Michael J. Yost (person) — Departed Chief Medical Officer
- June 30, 2024 (date) — Effective date of appointments and departure
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Adrian J. Wildfire has been appointed as the new Chief Medical Officer.
Who has been appointed as the new Chief Scientific Officer?
Dr. Robert J. B. Davies has been appointed as the new Chief Scientific Officer.
Who has departed from the role of Chief Medical Officer?
Dr. Michael J. Yost has departed from the role of Chief Medical Officer.
What is the effective date of these executive changes?
The changes are effective as of June 30, 2024.
What is Fennec Pharmaceuticals Inc.'s primary business sector?
Fennec Pharmaceuticals Inc. is in the Biological Products sector, specifically excluding diagnostic substances.
Filing Stats: 659 words · 3 min read · ~2 pages · Grade level 10.6 · Accepted 2024-07-01 17:38:59
Key Financial Figures
- $8.03 — rated options have an exercise price of $8.03 per common share and expire on June 30,
Filing Documents
- tm2418676d1_8k.htm (8-K) — 27KB
- tm2418676d1_ex10-1.htm (EX-10.1) — 40KB
- tm2418676d1_ex99-1.htm (EX-99.1) — 10KB
- tm2418676d1_ex99-1img001.jpg (GRAPHIC) — 5KB
- 0001104659-24-076936.txt ( ) — 265KB
- fencf-20240630.xsd (EX-101.SCH) — 3KB
- fencf-20240630_lab.xml (EX-101.LAB) — 33KB
- fencf-20240630_pre.xml (EX-101.PRE) — 22KB
- tm2418676d1_8k_htm.xml (XML) — 4KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 30, 2024, Adrian Haigh departed from his position as Fennec Pharmaceuticals Inc.'s (the "Company") Chief Operating Officer, a role Mr. Haigh transitioned to in August 2023 after serving nine years as an independent director of the Company. In connection with Mr. Haigh's departure as Chief Operating Officer, on June 30, 2024, the Company, the Company's subsidiary Fennec Pharmaceutics (EU) Limited, and Mr. Haigh entered into a Confidential Separation Agreement pursuant to which, among other terms customary for an agreement of this type, the Company agreed to accelerate the vesting of certain options held by Mr. Haigh to purchase up to 66,667 common shares of the Company. The accelerated options have an exercise price of $8.03 per common share and expire on June 30, 2027. The foregoing description of the Confidential Separation Agreement is qualified by the complete text of the Confidential Separation Agreement, a copy of which is attached at Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.
01
Item 8.01 Other Items. On July 1, 2024, the Company issued a press release announcing Mr. Haigh's departure as the Company's Chief Operating Officer. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 8.01, including the press release attached hereto, is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references this Form 8-K.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description Exhibit 99.1 Press Release dated July 1, 2024 Exhibit 10.1 Separation Agreement Adrian Haigh SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FENNEC PHARMACEUTICALS INC. Date July 1, 2024 By: /s/ Robert Andrade Robert Andrade Chief Financial Officer